The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry
- PMID: 29972871
- PMCID: PMC6546298
- DOI: 10.1002/jbmr.3543
The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry
Abstract
Hypoparathyroidism is a rare disorder that is associated with abnormal bone properties. Recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] in short-term studies has beneficial skeletal effects. Although rhPTH(1-84) will likely be used indefinitely, long-term effects on skeletal microstructure are unknown. We therefore studied histomorphometric changes with transiliac crest bone biopsies before and after 8.3 ± 1 years of rhPTH(1-84) in 13 hypoparathyroid subjects compared with 45 controls. Before institution of rhPTH(1-84), skeletal remodeling indices were markedly suppressed. With long-term treatment, indices of bone remodeling increased. Mineralizing surface increased by 26-fold (0.3 ± 1 to 7.9 ± 7%, p = 0.003), bone formation rate increased by 15-fold (0.003 ± 0.01 to 0.047 ± 0.05 μm2 /μm/day, p = 0.007), osteoid width doubled (1.9 ± 1 to 4.3 ± 1 lamellae, p = 0.017), and osteoid surface tripled (3.3 ± 3 to 10.8 ± 6%, p = 0.011). Bone resorption as measured by eroded surface increased (4.6 ± 2 to 7.5 ± 3%, p = 0.021). Structural changes demonstrated intratrabecular tunneling, with increases in cancellous bone volume (19.6 ± 5 to 29.1 ± 11%, p = 0.017) and trabecular number (1.8 ± 1 to 2.5 ± 1 #/mm, p = 0.025). Cortical porosity tended to increase (6.3 ± 5 to 9.5 ± 3%, p = 0.07). Mineralizing surface, osteoid surface, and eroded surface surpassed control levels, as did cancellous bone volume, trabecular number, and cortical porosity. These data, the first to reflect such long exposure of any PTH for any disease, illustrate that PTH establishes and maintains a new skeletal state for at least 8 years in hypoparathyroidism. © 2018 American Society for Bone and Mineral Research.
Trial registration: ClinicalTrials.gov NCT00473265.
Keywords: CORTICAL POROSITY; HISTOMORPHOMETRY; HYPOPARATHYROIDISM; RHPTH(1-84); TRABECULAR TUNNELING.
© 2018 American Society for Bone and Mineral Research.
Figures


Similar articles
-
Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.J Bone Miner Res. 2012 Aug;27(8):1811-20. doi: 10.1002/jbmr.1627. J Bone Miner Res. 2012. PMID: 22492501 Free PMC article. Clinical Trial.
-
Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis.J Bone Miner Res. 2018 Dec;33(12):2132-2139. doi: 10.1002/jbmr.3554. Epub 2018 Aug 8. J Bone Miner Res. 2018. PMID: 30088838
-
PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism.J Bone Miner Res. 2011 Nov;26(11):2727-36. doi: 10.1002/jbmr.452. J Bone Miner Res. 2011. PMID: 21735476 Free PMC article. Clinical Trial.
-
Skeletal Manifestations of Hypoparathyroidism.Endocrinol Metab Clin North Am. 2018 Dec;47(4):825-837. doi: 10.1016/j.ecl.2018.07.008. Endocrinol Metab Clin North Am. 2018. PMID: 30390816 Review.
-
Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism.Expert Opin Drug Saf. 2017 May;16(5):617-625. doi: 10.1080/14740338.2017.1311322. Epub 2017 Apr 3. Expert Opin Drug Saf. 2017. PMID: 28332412 Review.
Cited by
-
PTH Substitution Therapy for Chronic Hypoparathyroidism: PTH 1-84 and Palopegteriparatide.Curr Osteoporos Rep. 2025 Feb 22;23(1):12. doi: 10.1007/s11914-025-00905-6. Curr Osteoporos Rep. 2025. PMID: 39987371 Review.
-
Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes.Endocr Rev. 2025 Jul 15;46(4):576-620. doi: 10.1210/endrev/bnaf010. Endocr Rev. 2025. PMID: 40177730 Free PMC article. Review.
-
Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism.J Clin Endocrinol Metab. 2019 Nov 1;104(11):5136-5147. doi: 10.1210/jc.2019-01010. J Clin Endocrinol Metab. 2019. PMID: 31369089 Free PMC article.
-
Recombinant human parathyroid hormone (1-84) is effective in CASR-associated hypoparathyroidism.Eur J Endocrinol. 2020 Dec;183(6):K13-K21. doi: 10.1530/EJE-20-0710. Eur J Endocrinol. 2020. PMID: 33112267 Free PMC article.
-
Hypoparathyroidism.J Clin Endocrinol Metab. 2020 Jun 1;105(6):1722-36. doi: 10.1210/clinem/dgaa113. J Clin Endocrinol Metab. 2020. PMID: 32322899 Free PMC article. Review.
References
-
- Shoback D Clinical practice. Hypoparathyroidism. N Engl J Med 2008. July;359(4):391–403. Epub 2008 Jul 25. - PubMed
-
- Langdahl BL, Mortensen L, Vesterby A, Eriksen EF, Charles P. Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone 1996. February;18(2):103–8. Epub 1996 Feb 1. - PubMed
-
- Kruse K, Kracht U, Wohlfart K, Kruse U. Biochemical markers of bone turnover, intact serum parathyroid horn and renal calcium excretion in patients with pseudohypoparathyroidism and hypoparathyroidism before and during vitamin D treatment. Eur J Pediatr 1989. April;148(6):535–9. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical